<DrugInformationSummary id="CDR0000790948"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about daunorubicin hydrochloride and cytarabine liposome
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochlorideandcytarabineliposome">Daunorubicin Hydrochloride and Cytarabine Liposome</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000554979">liposome-encapsulated daunorubicin-cytarabine</TerminologyLink><GlossaryLink ref="CDR0000790285">daunorubicin hydrochloride and cytarabine liposome</GlossaryLink><USBrandNames><USBrandName>Vyxeos</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>DAW-noh-ROO-bih-sin HY-droh-KLOR-ide â€¦ sy-TAYR-uh-been LY-poh-some</TermPronunciation><MediaLink ref="CDR0000791469" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000791468" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Daunorubicin Hydrochloride and Cytarabine Liposome</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Daunorubicin hydrochloride and cytarabine liposome
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">Acute myeloid leukemia</GlossaryTermRef></Strong> (AML) that is newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef>. It is used in adults with therapy-related AML (tAML) or AML with <GlossaryTermRef href="CDR0000045953" dictionary="Cancer.gov" audience="Patient">myelodysplasia</GlossaryTermRef>-related changes (AML-MRC).</ListItem>
   
   </ItemizedList>
  <Para id="_4">Daunorubicin hydrochloride and cytarabine liposome is a <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination</GlossaryTermRef> form of <GlossaryTermRef href="CDR0000583859" dictionary="Cancer.gov" audience="Patient">daunorubicin hydrochloride</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045155" dictionary="Cancer.gov" audience="Patient">cytarabine</GlossaryTermRef> contained inside <GlossaryTermRef href="CDR0000615392" dictionary="Cancer.gov" audience="Patient">liposomes</GlossaryTermRef> (very tiny particles of fat). This form may work better than other forms of these drugs and have fewer <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef>. Also, because its effects last longer in the body, it doesn't need to be given as often. For more information about daunorubicin hydrochloride and <GlossaryTermRef href="CDR0000045155" dictionary="Cancer.gov" audience="Patient">cytarabine</GlossaryTermRef> that may apply to this combination drug, see the Drug Information Summaries for <DrugRef href="CDR0000649927" url="/about-cancer/treatment/drugs/daunorubicinhydrochloride">Daunorubicin Hydrochloride</DrugRef> and <DrugRef href="CDR0000540242" url="/about-cancer/treatment/drugs/cytarabine">Cytarabine</DrugRef>.</Para><Para id="_5">Daunorubicin hydrochloride and cytarabine liposome
         is also being studied in the treatment of other types of
         <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.</Para>
 </Section><Section id="_About"><Title>More About Daunorubicin Hydrochloride and Cytarabine Liposome</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/554979">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.5">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a617045.html">Daunorubicin Hydrochloride and Cytarabine Liposome</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.6"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.7">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C67504">Find Clinical Trials for Liposome-encapsulated Daunorubicin-cytarabine</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2017-09-19</DateFirstPublished><DateLastModified>2020-10-07</DateLastModified></DrugInformationSummary>
